For more information: Stephanie Perry RoseStreet Labs (602) 431-4747 stephanie.perry@flipchip.com

RoseStreet Labs Acquires Breath Acetone Monitoring Technology From The Dow Chemical Company

~Technology will accelerate development of over-the-counter, low-cost metabolism monitor to aid in individual weight control.~

PHOENIX, Arizona, September 8, 2005 – RoseStreet Labs, an emerging wireless sensor company, today announced the acquisition of breath acetone monitoring technology from The Dow Chemical Company (NYSE: DOW). The technology, which provides rapid feedback of dietary and metabolic conditions, will be incorporated into RoseStreet's LifeStyleTM Monitor for dietary and obesity biofeedback control. The acquisition includes both a working prototype and an extensive portfolio of intellectual property for acetone breath monitoring of fat metabolism, developed by Dow over the past four years. Financial terms were not disclosed.

The Dow-developed technology will accelerate the development of RoseStreet's LifeStyle Monitor, which will provide consumers with an over-the-counter, low-cost solution for individual weight control by keeping track of acetone levels in the breath. Acetone breath levels are strongly correlated with fat metabolism, are independent of water retention or water loss, and are sensitive to exercise regimens. The LifeStyle Monitor will therefore provide individuals with robust feedback on their body's fat metabolism to aid in their weight control efforts.

RoseStreet expects to launch the LifeStyle Monitor in 2006 as a lifestyle aid, and also plans on clinical versions by 2008. "We are very please to have the opportunity to accelerate our LifeStyle Monitor product development with Dow's outstanding technology, including advancements in proprietary enzyme technology", said Bob Forcier, President & CEO, RoseStreet Labs. "Obesity, which can lead to cardio-vascular diseases and the onset of diabetes, is one of our nation's greatest health problems. RoseStreet Labs is dedicated to developing technologies, such as the LifeStyle Monitor, which offer solutions and the potential to improve the quality of life from many people."

Commenting on the sale, Dow's New Business Development Leader, Kathy Hofius, said: "Over the past four years, Dow has advanced this exciting new technology to the point of developing a highly successful prototype with tremendous commercial potential. However, its continued success would require us to move into areas of the healthcare market which simply do not align with Dow's strategic direction. We are very pleased, therefore, to have found a buyer in RoseStreet – a company with the business model required to commercialize the technology and put it to work in the healthcare arena."

About The RoseStreet Labs Company

RoseStreet Labs, LLC, is a supplier of products and services for wireless infrastructure and sensors in the Life Sciences, Renewable Energy and Homeland Security markets. RoseStreet Labs actively provides interconnect and assembly R&D for next generation products and is the parent to FlipChip International, LLC, the global leader in flip chip bumping, wafer-level packaging, semiconductor dicing, tape & reel, known-good-die and die sales. RoseStreet Labs, FCI, and its newly opened R&D facility are located in Phoenix, Arizona. Visit www.rosestreetlabs.com, www.flipchip.com

About The Dow Chemical Company

Dow is a leader in science and technology, providing innovative chemical, plastic and agricultural products and services to many essential consumer markets. With annual sales of \$40 billion, Dow serves customers in 175 countries and a wide range of markets that are vital to human progress: food, transportation, health and medicine, personal and home care, and building and construction, among others. Committed to the principles of sustainable development, Dow and its 43,000 employees seek to balance economic, environmental and social responsibilities. Visit www.dow.com for more information.

TM Trademark of RoseStreet Labs